A meta-analysis of 1,047 patients found that both intramedullary (IM) nailing and endoprosthetic (EP) reconstruction are effective options for treating femoral metastases, with the best choice depending on patient survival outlook and treatment goals. The study showed that IM nailing is associated with fewer early complications, including lower infection rates and fewer reoperations within the […]
Results show that cadonilimab, a bispecific antibody, combined with chemotherapy is highly effective as a first-line treatment for advanced or recurrent endometrial cancer. In the study of 41 evaluable patients, 78% experienced significant tumor shrinkage and 97.6% achieved disease control, meaning most patients had either tumor reduction or stable disease. The median progression-free survival was
Cadonilimab Combo Shows Strong First-Line Results in Advanced Endometrial Cancer Read More »
Data shows that niraparib (Zejula) maintenance therapy for ovarian cancer is generally safe and manageable outside of clinical trials. The study followed 218 patients for a median of 22.6 months and found that blood-related side effects were common but usually mild to moderate. These included low platelets (60.1%), anemia (58.7%), and low white blood cells
Real-World Study Confirms Safety of Niraparib Maintenance Therapy in Ovarian Cancer Read More »
Findings show that combining abemaciclib (Verzenio) with letrozole is an effective treatment for advanced or recurrent endometrial cancer. The study found strong disease control, especially in patients who had not previously received chemotherapy. Overall, 56.9% of patients were progression-free at 6 months, rising to 71.4% in chemo-naïve patients. The median progression-free survival was 9.5 months
Abemaciclib and Letrozole Combo Shows Promise in Advanced Endometrial Cancer Read More »
The phase 3 ROSELLA study found that adding relacorilant (Lifyorli) to nab-paclitaxel (Abraxane) improves survival for patients with platinum-resistant ovarian cancer. Based on these results, the combination was approved by the U.S. Food and Drug Administration in March 2026 and is now recommended in NCCN treatment guidelines. The study showed that patients receiving the combination
FDA-Approved Drug Combo Improves Survival in Platinum-Resistant Ovarian Cancer Read More »
Researchers have discovered a new way that Acute Myeloid Leukemia (AML) hides from the immune system. Scientists had long believed that a protein called CD47 was the main signal preventing immune cells from attacking leukemia. However, this study found that CD47 plays a weaker role in humans than expected, which may explain why drugs targeting
New “Sugar Shield” Helping Leukemia Cells Evade the Immune System Read More »
The U.S. Food and Drug Administration has accepted the resubmitted New Drug Application for TLX101-Px, also known as Pixclara, a new PET imaging agent designed to better detect and evaluate brain tumors in both adults and children. One of the biggest challenges in treating gliomas is telling the difference between true tumor growth and changes
FDA Reviews Pixclara Imaging Agent to Improve Brain Tumor Diagnosis and Monitoring Read More »
Results show that combining hormonal therapy with immunotherapy may offer a promising alternative to chemotherapy for advanced salivary gland cancer. The treatment combined goserelin, a hormone therapy, with pembrolizumab. The study reported a 27.7% overall response rate and a 78% disease control rate. Patients stayed on treatment for a median of 12.1 months, and some
Hormone and Immunotherapy Combo Shows Promise in Advanced Salivary Gland Cancer Read More »
The BRIDGE project, a collaboration between ITQB NOVA and IPOFG Lisbon, is working on new ways to better understand and treat aggressive breast cancer by studying how tumors interact with the immune system. Researchers are focusing on finding biomarkers—biological signals that can predict how quickly a cancer will grow and how it will respond to
BRIDGE Project Aims to Personalize Treatment for Aggressive Breast Cancer Read More »
Researchers have found that zeaxanthin, a natural compound commonly used for eye health, may help the immune system fight cancer more effectively. The study shows that zeaxanthin works by stabilizing T-cell receptors, allowing CD8+ T cells—the body’s main cancer-fighting immune cells—to better recognize and attack tumor cells. In animal studies, zeaxanthin slowed tumor growth and
Common Eye Nutrient Zeaxanthin Shows Promise in Boosting Cancer Immunotherapy Read More »